New drug ORKA-002 tested in humans for the first time

NCT ID NCT06944379

First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 41 times

Summary

This Phase 1 trial is the first time ORKA-002 is being tested in humans. It involves 24 healthy adults to check the drug's safety, tolerability, and how the body processes it. Participants receive a single injection of either ORKA-002 or a placebo. The study is not designed to treat any disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Oruka Therapeutics Investigative Site

    Christchurch, New Zealand, New Zealand

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ORKA-002

What could go wrong

This is a very early Phase 1 trial with only 24 healthy people. It tests safety, not effectiveness, so it may not lead to any treatment.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.